Gossamer Bio Short Long Term Debt Total Over Time
| GOSS Stock | USD 0.70 0.04 6.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Gossamer Bio Performance and Gossamer Bio Correlation. Gossamer |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gossamer Bio. If investors know Gossamer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gossamer Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.466 | Return On Assets (0.11) | Return On Equity (0.90) |
The market value of Gossamer Bio is measured differently than its book value, which is the value of Gossamer that is recorded on the company's balance sheet. Investors also form their own opinion of Gossamer Bio's value that differs from its market value or its book value, called intrinsic value, which is Gossamer Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gossamer Bio's market value can be influenced by many factors that don't directly affect Gossamer Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gossamer Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Gossamer Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gossamer Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Gossamer Bio and related stocks such as Biomea Fusion, Stoke Therapeutics, and Akero Therapeutics Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMEA | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 2.9 M | 2.3 M | 10.3 M | 10.8 M |
| STOK | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 1.5 M | 2.4 M | 6.8 M | 7.2 M |
| AKRO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.5 M | 10.9 M | 26.3 M | 27.6 M |
| REPL | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 41.8 M | 33.3 M | 32.8 M | 60.8 M | 75.9 M | 46 M |
| LYRA | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 2.4 M | 1.5 M | 2.2 M | 26.9 M | 28.2 M |
| KRON | 771 K | 771 K | 771 K | 771 K | 771 K | 771 K | 771 K | 771 K | 771 K | 528 K | 32.1 M | 33.8 M | 31.1 M | 28.3 M | 23.2 M |
| PASG | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 26.3 M | 21.4 M |
| BDTX | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 200.6 M | 8.7 M | 28.5 M | 28.1 M | 25.3 M | 46.6 M |
| ALEC | 48 M | 48 M | 48 M | 48 M | 48 M | 48 M | 48 M | 48 M | 48 M | 48 M | 51.3 M | 47.6 M | 43.3 M | 38.9 M | 36.7 M |
| ABOS | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 105 K | 28.5 M | 29.9 M |
| INZY | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 3.4 M | 6.8 M | 46.6 M | 48.9 M |
| XFOR | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 15.3 M | 12.2 M | 9.6 M | 22.9 M | 38.4 M | 39.8 M | 38.4 M | 58.3 M | 29.6 M |
| FDMT | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.1 M | 14.7 M | 12.6 M |
Gossamer Bio and related stocks such as Biomea Fusion, Stoke Therapeutics, and Akero Therapeutics Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Gossamer Bio | GOSS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.7
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.